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S100A4, also known as CAPL, pEL98, mts1, p9Ka, 18A2, 42A
and FSP1, is a member of the S100 subfamily of calcium-binding
proteins (Hilt and Kligman, 1991; Celio et al, 1996; Schäfer and
Heinzmann, 1996). Its expression has been shown to be associated
with cell immortalization (Goto et al, 1988), cell growth (Jackson-
Grusby et al, 1987), differentiation of myoepithelial cells
(Barraclough et al, 1987) and promyelocytic leukaemia cells
(Takenaga et al, 1994b), fibrogenesis (Strutz et al, 1995) and
tumour progression (Grigorian et al, 1996). In addition, several
lines of evidence indicate that S100A4 is directly involved in
tumour cell invasion and metastasis. Ebralitze et al reported that
the expression of S100A4 was elevated in metastatic tumour cells
(Ebralidze et al, 1989). We and others have shown that the
increased expression of S100A4 in tumour cells by introduction of
the S100A4 gene resulted in an enhancement of cell motility and
invasive and metastatic potential of tumour cells (Davies et al,
1993; Parker et al, 1994; Takenaga et al, 1994a). On the other
hand, reduction of the expression of S100A4 by means of anti-
sense S100A4 RNA or anti-S100A4 ribozyme in high-metastatic
tumour cells resulted in the suppression of their invasive and
metastatic capabilities (Grigorian et al, 1993; MæLandsmo et al,
1996; Takenaga et al, 1997a). Although the precise functions of
the S100A4 protein are not fully understood, recent studies impli-
cate that the protein interacts with cytoskeletal proteins such as
non-muscle tropomyosins (Takenaga et al, 1994c, 1994d) and
myosin (Kriajevska et al, 1994; Ford and Zain, 1995) in a Ca2+-
dependent manner and thereby modulates cell motility (Takenaga
et al, 1994a, 1994d; Ford and Zain, 1995). Importantly, several
studies have shown that S100A4 may also play a role in invasion
and metastasis of human tumours including breast (Pedrocchi et al,
1994; Ilg et al, 1996) and colorectal carcinomas (Ilg et al, 1996;
Takenaga et al, 1997b).
Metastasis comprises a complex series of interactions between
tumour cells and their environment (Radinsky, 1995). At each
step, tumour cells are exposed to a variety of local factors such
as hormones, growth factors and cytokines. These factors
undoubtedly modulate the metastasis-associated properties of
tumour cells such as growth potential, secretion of type IV
collagenolytic activity, cell migration, cell adhesion and natural
killer (NK) cell sensitivity. Since it is largely unknown whether the
S100A4 expression in tumour cells is also influenced by such
factors, the effects of various growth factors and cytokines on the
expression of S100A4 in human colon adenocarcinoma cells were
examined. In this study, the fact that interferon gamma (IFN-g)
efficiently suppresses the S100A4 expression and reduces the
motile ability in the cells is demonstrated.
MATERIALS AND METHODS
Reagents
Recombinant human IFN-a (specific activity; 3 ´ 108 IU mg–1)
and IFN-g (specific activity; 3 ´ 107 IU mg–1) were purchased from
Pepro Tech EC Ltd (London, UK). Human IFN-b (specific
activity; 1 ´ 105 IU mg–1) and mouse monoclonal anti-human IFN-
g receptor (clone GIR-208) were obtained from Sigma Chemicals
Co. (St Louis, MO, USA). Recombinant human tumour necrosis
factor-a (TNF-a) was purchased from Gibco BRL (Grand Island,
NY, USA).
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Summary S100A4 belongs to the S100 subfamily of calcium-binding proteins and has been suggested to be directly involved in invasion and
metastasis of rodent and human tumour cells. The present study demonstrates that interferon gamma (IFN-g), but not IFN-a and IFN-b, down-
regulates the S100A4 mRNA level in colon adenocarcinoma WiDr cells in time- and dose-dependent manners. The effect was not associated
with any cytotoxicity and was specific for the S100A4 mRNA, since the levels of the S100A6 and GAPDH mRNAs were not significantly
affected by the treatment. IFN-g also strongly suppressed the S100A4 mRNA expression in HT-29 cells, but weakly in Colo201 cells. Flow
cytometric analysis revealed that the level of the IFN-g receptor expression in Colo201 cells was lower than that in WiDr and HT-29 cells,
suggesting that the suppression of the S100A4 expression by IFN-g depends on the amount of cell surface IFN-g receptor protein. IFN-g had
no effect on the transcription rate of the S100A4 gene but reduced the stability of the S100A4 mRNA. WiDr cells treated with IFN-g showed
reduced motile ability, further supporting the assumption that the S100A4 gene product is involved in controlling cell motility.
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Human colon adenocarcinoma cell lines, WiDr, Colo201 and
HT-29, were obtained from the American Type Culture Collection
(Rockville, MD, USA). They were cultured in RPMI-1640
medium supplemented with 10% heat (56°C, 30 min)-inactivated
fetal bovine serum, 100 mg ml–1 streptomycin and 100 units per ml
penicillin.
Western blot analysis
Cells were lysed in extraction buffer (150 mM sodium chloride,
50 mM Tris-HCl (pH 7.5), 1% Triton X-100, 1 mM EGTA and 1
mM phenylmethylsulphonyl fluoride) (Takenaga et al, 1994a). Cell
lysates were centrifuged at 10 000 g for 10 min, and the super-
natant was used for immunoblot analysis. Immunoblot analysis
was carried out as described previously (Takenaga et al, 1994a)
using anti-S100A4 polyclonal antibody and an enhanced chemilu-
minescence Western blotting detection kit (Amersham).
Northern blot analysis
Twenty micrograms of RNA which was extracted with guani-
dinium thiocyanate were electrophoresed on 1% agarose gel
containing formaldehyde and transferred to nylon filters
(Sambrook et al, 1989). Blots were hybridized with a 32P-labelled
human S100A4, S100A6 (a gift from Dr DT Denhardt) or glycer-
aldehyde 3-phosphate dehydrogenase (GAPDH) cDNA which was
prepared by the random primer method (Sambrook et al, 1989).
Filters were finally washed at 50°C in 0.2 ´ saline–sodium citrate
(SSC) containing 0.1% sodium dodecyl sulphate (SDS).
Evaluation of S100A4 mRNA stability
Untreated cells and cells treated with 300 IU ml–1 IFN-g for 10 h
were incubated with 5 mg ml–1 actinomycin D for up to 12 h to
block further transcription. Total RNA was extracted and
subjected to Northern blot analysis. The blots were hybridized
with either an S100A4 cDNA probe or a human GAPDH cDNA
probe. After quantifying the intensities of bands by scanning the
autoradiograms, the levels of S100A4 mRNA were normalized to
those of GAPDH mRNA.
Nuclear run-off transcription
RNA chains were elongated in nuclei isolated from untreated cells
and cells treated with 300 IU ml–1 IFN-g for 20 h. The procedures
for isolation of nuclei and nuclear run-off transcription were
carried out as described elsewhere (Groudine et al, 1981).
Denatured cDNA inserts (4 mg) were immobilized on a single strip
of nylon membrane and hybridized to 32P-labelled RNA transcripts
at 42°C for 60 h.
Fluorescence-activated cell-sorting analysis of IFN-g
receptor (IFN-g-R) expression
All procedures were carried out at 4°C. Cells were washed three
times with Dulbecco’s phosphate-buffered saline (PBS) and incu-
bated for 20 min in PBS containing 3% bovine serum albumin
(BSA) and 0.1% normal goat serum. The cells were washed with
PBS and then incubated for 1 h with either PBS/BSA or a 1:100
dilution of mouse anti-human IFN-g-R monoclonal antibody,
washed, and then incubated for 30 min with a 1:200 dilution of a
fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse
secondary antibody in PBS/BSA. After washing, cells were fixed
with 3% paraformaldehyde and then analysed by fluorescence-
activated cell sorting (FACSCAN, Beckton Dickinson, Mountain
View, CA, USA).
Cell motility assay
Cell motility was assessed by phagokinetic track assay as
described elsewhere (Takenaga et al, 1994a, 1997a). Cells were
incubated for 24 h in growth medium containing 300 IU ml–1
IFN-g, washed, and then seeded onto coverslips coated with 10 mg
ml–1 BSA and colloidal gold particle. Cells were seeded at a
concentration of 2000 cells per coverslip and incubated for further
24 h in the presence of 300 IU ml–1 IFN-g. The cells were fixed
with 3% formaldehyde and then coverslips were mounted. The
areas where cells had moved were digitized and measured. Cell
motility was evaluated by measuring more than 50 areas free of
the gold particles.
RESULTS
Effect of IFN-g on the S100A4 mRNA expression in
human colon adenocarcinoma WiDr cells
The effects of IFN-g and TNF-a on the expression of S100A4
mRNA were examined in WiDr cells, which are reported to
express S100A4 (Takenaga et al, 1997b). Treatment of the cells
with 300 IU ml–1 IFN-g for 48 h resulted in a striking suppression
of the S100A4 expression (Figure 1A). However, the expressions
of S100A6 and GAPDH mRNAs were not significantly altered by
the IFN-g treatment (Figure 1A). IFN-a (300 IU ml–1), IFN-b
(300 IU ml–1) and TNF-a (10 ng ml–1) showed no effect on the
S100A4 expression (Figure 1 A,B). These results indicate that the
suppression of S100A4 is specific for IFN-g. The inhibition of the
S100A4 expression by IFN-g was clearly detectable as early as
10 h after the treatment (Figure 2A) and at the concentrations
above 200 IU ml–1 (Figure 2B). Western blot analysis also revealed
a reduction in the S100A4 protein in IFN-g-treated WiDr cells
(Figure 1C). The effects of interleukin 1 (IL-1), IL-6 and various
growth factors such as fibroblast growth factor, epidermal growth
factor, hepatocyte growth factor and insulin growth factors on the
S100A4 expression were also investigated. The results showed
that they neither stimulate nor inhibit the S100A4 expression (data
not shown).
Effect of IFN-g on S100A4 expression and cell surface
IFN-g-R expression in colon adenocarcinoma cells
To examine whether IFN-g suppresses the expression of S100A4
in other colon adenocarcinoma cells, Colo201 and HT-29 cells,
both of which express S100A4 (Takenaga et al, 1997b), were incu-
bated with 300 IU ml–1 IFN-g for 48 h. The results in Figure 3
show that IFN-g significantly suppressed the S100A4 expression
in HT-29 cells as observed in WiDr cells, but only weakly in
Colo201 cells. The reason might be due to the lower expression of
cell surface IFN-g-R in Colo201 cells than in WiDr and HT-29
cells. To address this question, the cells were incubated with an
anti-IFN-g-R monoclonal antibody followed by incubation with a
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fluorescence-activated cell sorting. The results showed that the
expression of cell surface IFN-g-R was indeed lower in Colo201
cells than in WiDr and HT-29 cells (Figure 4).
Effects of IFN-g on S100A4 gene transcription and
S100A4 mRNA stability in WiDr cells
The molecular mechanism by which IFN-g down-regulates the
steady-state level of S100A4 mRNA was explored by examining
the effect of IFN-g on the S100A4 gene transcription. In vitro tran-
scription analyses showed that the transcriptional rate of S100A4
mRNA as well as that of GAPDH mRNA in IFN-g-treated cells
was indistinguishable from that in untreated cells (Figure 5A). The
decay rate of S100A4 mRNA was next compared between WiDr
cells and the cells treated with IFN-g. As shown in Figure 5B, the
level of S100A4 mRNA in control cells did not change during a
12-h incubation period with actinomycin D, indicating that the
S100A4 mRNA is highly stable as reported previously (Grigorian
et al, 1994). On the other hand, the S100A4 mRNA in IFN-g-
treated cells was decayed more rapidly than that in untreated cells.
These results suggest that the down-regulation of the steady-state
level of the S100A4 mRNA in WiDr cells treated with IFN-g was
partly due to the reduced S100A4 mRNA stability.
Effect of IFN-g on cell motility of WiDr cells
WiDr cells were pretreated with 300 IU ml–1 IFN-g for 24 h and
then subjected to the motility assay in the presence of IFN-g for
another 24 h. As shown in Figure 6, the motile ability of WiDr
cells treated with IFN-g was significantly lower than that of
untreated cells.
DISCUSSION
The present study has shown that IFN-g, but not IFN-a and IFN-b,
suppressed the expression of S100A4 gene in colon adenocarci-
noma cells. Several lines of evidence support that the suppression
is not due to its cytotoxicity. First, the expressions of S100A6 and
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Figure 1 Effects of interferons on the expression of S100A4 in WiDr cells.
(A) WiDr cells were cultured in the presence or absence of 300 IU ml–1 IFN-g
or 10 ng ml–1 TNF-a for 48 h. Total RNA isolated from untreated and
cytokine-treated cells was electrophoresed on 1% gel containing
formaldehyde and transferred to nylon filters. Blots were hybridized with a
32P-labelled human S100A4, S100A6 or GAPDH cDNA. Ethidium bromide
staining of the gel was also shown. (B) WiDr cells were cultured in the
presence or absence of 300 IU ml–1 IFN-a, IFN-b or IFN-g for 48 h. RNA blot
was hybridized with a 32P-labelled human S100A4 cDNA. (C) WiDr cells
were cultured in the presence or absence of 300 IU ml–1 IFN-a, IFN-b or IFN-
g for 48 h. Immunoblot analysis was performed as described in Materials and
Methods using anti-S100A4 antiserum
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Figure 2 Effect of IFN-g on the expression of S100A4 mRNA in WiDr cells.
(A) Time course. WiDr cells were incubated with 300 IU ml–1 IFN-g for the
indicated times. (B) Dose–response. WiDr cells were incubated with various
concentrations of IFN-g for 48 h. Total RNA isolated from untreated and IFN-
g-treated cells was subjected to Northern blot analysis. Blots were hybridized
with a 32P-labelled human S100A4 cDNA. Ethidium bromide staining of the
gel was also shownGAPDH mRNAs were not significantly suppressed by IFN-g.
Second, TNF-a (10 ng ml–1), which inhibited the cell growth to a
similar extent as IFN-g (300 units ml–1) (approximately 20%) did not
suppress the S100A4 mRNA expression. Third, the suppression of
the S100A4 mRNA expression was observed as early as  10h after
the IFN-g treatment, a time when the cells were fully viable.
IFN-g has been shown to modulate expressions of a variety of
genes (Sen and Lengyel, 1992). The mechanisms for the down-
regulation of genes caused by IFN-g are less understood than
those for the up-regulation of genes in which the sequences in the
5¢-flanking regulatory region, as well as transcription factors, are
implicated (Sen et al, 1992). The expression of type II collagen
gene has been shown to be down-regulated by IFN-g, primarily at
the transcriptional level (Goldring et al, 1994). On the other hand,
genes coding for c-fos (Radzich and Varesio, 1991), c-myc (Harel-
Bellan et al, 1988), transferrin receptor (Bourgeade et al, 1992)
and cystic fibrosis transmembrane conductance regulator
(Besançon et al, 1994) have been post-transcriptionally modulated
by IFN-g. To examine the mechanisms by which IFN-g suppresses
the S100A4 gene expression, the transcriptional rate of the
S100A4 gene and the mRNA stability were examined. The results
showed that IFN-g did not affect its transcription rate but reduced
the mRNA stability, indicating that the expression of the S100A4
gene expression in human colon adenocarcinoma cells is down-
regulated by IFN-g at the post-transcriptional level. The mecha-
nism by which IFN-g reduces the S100A4 mRNA stability is an
interesting issue to be solved. Since it has recently been demon-
strated that the methylation of S100A4 gene is crucial for the gene
expression in human colon adenocarcinoma cell lines (Nakamura
and Takenaga, 1998), the DNA methylation status of the S100A4
gene before and after the treatment of WiDr cells with IFN-g was
also examined. However, there was no detectable difference in the
degree of DNA methylation between untreated and IFN-g-treated
WiDr cells (data not shown).
Transfection of v-src-transformed 3Y1 cells and mouse
mammary adenocarcinoma CSMLO cells with S100A4 gene
resulted in an increased cell motility (Takenaga et al, 1994a; Ford
et al, 1995). Conversely, the expression of antisense S100A4
mRNA in S100A4-expressing Lewis lung carcinoma cells lowered
cell motility (Takenaga et al, 1997a). These results collectively
support the assumption that S100A4 participates in regulating cell
motility. The present study suggested that IFN-g-treated WiDr cells
became less motile than untreated cells through the suppression of
the S100A4 expression. However, the involvement of other factors
in the inhibition of cell motility of WiDr cells by IFN-g cannot be
neglected, because IFN-g possesses a variety of biological effects.
Colo201 cells that express a lower level of IFN-g-R than WiDr
and HT-29 cells were more refractory to IFN-g in terms of the inhi-
bition of the S100A4 mRNA expression. This result suggests that
the inhibition of the S100A4 mRNA expression by IFN-g is
mediated by cell surface IFN-g-R. If this is the case, an attempt to
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Figure 3 Effects of IFN-g on the expression of S100A4 mRNA in various
human colorectal carcinoma cells. WiDr, Colo201 and HT-29 cells were
incubated with 300 IU ml–1 IFN-g for 48 h. Total RNA isolated from untreated
and IFN-g-treated cells was subjected to Northern blot analysis. Blots were
hybridized with a 32P-labelled human S100A4 cDNA. Ethidium bromide
staining of the gel was also shown
Figure 4 Flow cytometric analysis of IFN-g-R expression in various human colorectal carcinoma cells. (A) WiDr, (B) Colo201, (C) HT-29. Cells were incubated
in the absence (- - - -) or presence (——) of anti-IFN-g-R monoclonal antibodies. Cells were then analysed for IFN-g-R expression as described in Materials and
Methods
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ABCincrease the cell surface IFN-g-R in Colo201 cells may influence
the sensitivity of the cells to IFN-g. Since it has been reported that
IL-1 and TNF-a are able to increase the cell surface IFN-g-R
expression in colon carcinoma cells (Raitano and Korc, 1993), the
effects of IL-1 (1000 units per ml) and TNF-a (20 ng ml–1) on the
cell surface IFN-g-R expression in Colo201 cells were prelimi-
narily examined. It was found that IL-1 caused an approximately
twofold increase in the expression of IFN-g-R (data not shown).
Colo201 cells were then simultaneously treated with IFN-g and
IL-1, and the S100A4 mRNA expression was measured. The
results showed that IL-1 augmented the suppressive effect of
IFN-g on S100A4 expression (data not shown). Therefore, the
combination treatment of colon adenocarcinoma cells with IFN-g
and IL-1 would be more effective in reducing the S100A4 mRNA
expression and thereby in suppressing invasive and metastatic
potential of colon adenocarcinoma cells.
Previous reports have shown that IFN-g shows either a
suppressing or an enhancing effect on metastasis of tumour cells.
IFN-g inhibits metastasis of mouse ovarian and lung tumour cells
(Ossina et al, 1997), renal adenocarcinoma cells (Yanagihara et al,
1994) and human non-small-cell lung cancer cells (Masumori
et al, 1995). By contrast, it enhances experimental metastatic
potential of colon 26 adenocarcinoma cells (An et al, 1996) and
B16 melanoma cells (Ramani and Balkwill, 1987). These results
may be due to the time of treatment of the cells with IFN-g, as
suggested by some investigators (McMillan et al, 1987), or the
properties of each cell line. Unfortunately, it is largely unknown
whether IFN-g influences invasiveness and metastasis of human
colon adenocarcinoma cells. Therefore, the effects of IFN-g on
these phenotypes should be further clarified.
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Figure 5 Effect of IFN-g on transcription rate of the S100A4 gene and on
the stability of S100A4 mRNA in WiDr cells. (A) Nuclear run-off analysis of
the S100A4 gene transcription in untreated and IFN-g-treated cells. Nuclei
were isolated after 20-h treatment with 300 IU/ml IFN-g and used for in vitro
run-off transcription. Denatured S100A4 or GAPDH cDNA inserts were
bound to nylon filters and hybridized to the 32P-labelled transcripts.
(B) Stability of S100A4 mRNA in untreated (•) and IFN-g-treated (l l) cells.
After 10-h treatment of the cells with 300 IU ml–1 IFN-g, cells were exposed to
actinomycin D (5 mg ml–1) for the indicated times. RNA blots were hybridized
with a 32P-labelled S100A4 or GAPDH cDNA. The intensities of bands were
quantified by scanning the autoradiograms, and S100A4 mRNA levels were
normalized to those of GAPDH and expressed as % of control
4
3
2
1
0
None IFN- g
A
B
Figure 6 Effect of IFN-g on cell motility of WiDr cells. Cells that had been
incubated for 24 h in growth medium containing 300 IU ml–1 IFN-g were
washed and then subjected to the motility assay for 24 h in the presence of
300 IU ml–1 IFN-g. (A) Measured migrated area of untreated and IFN-g-
treated WiDr cells. (B) Phagokinetic track patterns produced by untreated
(upper panel) and IFN-g-treated WiDr cells (lower panel)
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